Compare Amgen, Inc. (AMGN) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Rigetti Computing Inc — how do they compare? Amgen, Inc. trades at $356.43 (market cap $196.12B), while Rigetti Computing Inc trades at $15.66 (market cap $5.50B). The key difference: Amgen, Inc. is far larger — about 35.7× Rigetti Computing Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Rigetti Computing Inc pays none. Which is the better fit depends on your goals.
| AMGN | RGTI | |
|---|---|---|
Market Cap | $196.12B | $5.50B |
Sector | Health | Technology |
52-Week High | $388.16 | $56.34 |
52-Week Low | $271.18 | $12.18 |
Enterprise Value | $241.41B | $5.09B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Rigetti Computing (RGTI) trades at $16.54, down 2.65% on the day, with a bearish technical signal despite recent earnings beats. The company shows severe financial strain with a net income margin of -2,253.59% and negative cash flow from operations of -$58.54M in 2025, though it maintains a debt-free position with $569M cash. Analyst consensus remains strongly bullish with 85.71% buy ratings and a $32.67 price target, highlighting government funding and quantum computing advancements as key catalysts.
The stock presents high-risk, high-reward potential driven by speculative quantum technology growth versus fundamental weaknesses. Near-term risks include cash burn sustainability and commercial adoption timelines, while upside hinges on execution against long-term quantum roadmaps and competitive positioning in a nascent industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
